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Labelling of Endogenous Target Protein via N–S Acyl Transfer- 
Mediated Activation of N-Sulfanylethylanilide  
Masaya Dendaa, Takuya Morisakia, Taiki Kohikia, Jun Yamamotoa, Kohei Satoa,b, Ikuko Sagawac, 
Tsubasa Inokumaa, Youichi Satoa, Aiko Yamauchia, Akira Shigenaga*a,d and Akira Otaka*a 
The ligand-dependent incorporation of a reporter molecule (e.g., fluorescence dye or biotin) onto a endogenous target 
protein has emerged as an important strategy for elucidating protein function using various affinity-based labelling reagents 
consisting of reporter, ligand and reactive units. Conventional labelling reagents generally use a weakly activated reactive 
unit, which can result in the non-specific labelling of proteins in a ligand-independent manner. In this context, the activation 
of a labelling reagent through a targeted protein-ligand interaction could potentially overcome the problems associated with 
conventional affinity-based labelling reagents. We hypothesized that this type of protein-ligand-interaction-mediated 
activation could be accomplished using N-sulfanylethylanilide (SEAlide) as the reactive unit in the labelling reagent. 
Electrophilically unreactive amide-type SEAlide can be activated by its conversion to the corresponding active thioester in 
the presence of a phosphate salt, which can act as an acid-base catalyst. It has been suggested that protein surfaces 
consisting of hydrophilic residues such as amino, carboxyl and imidazole groups could function as acid-base catalysts. We 
therefore envisioned that a SEAlide-based labelling reagent (SEAL) bearing SEAlide as a reactive unit could be activated 
through the binding of the SEAL with a target protein. Several SEALs were readily prepared in this study using standard 9-
fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase protocols. These SEAL systems were subsequently applied to the 
ligand-dependent labelling of human carbonic anhydrase (hCA) and cyclooxyganese 1. Although we have not yet obtained 
any direct evidence for the target protein-mediated activation of the SEAlide unit, our results for the reaction of these SEALs 
with hCA1 or butylamine indirectly support our hypothesis. The SEALs reported in this study represent valuable new entries 
to the field of affinity-based labelling reagents and are expected to show great utility in  protein labelling. 
Introduction 
Affinity-based labelling has recently attracted considerable 
attention as an efficient strategy for the introduction of 
reporter units (e.g., fluorescent dyes) onto the target proteins 
of bioactive compounds, with the resulting reporter-labelled 
proteins being used to analyze protein functions.1-4 The affinity-
based labelling reagents generally used in this method are 
composed of three functional units, including (1) a ligand unit 
for the selective labelling of a target protein; (2) a reporter unit 
for the visualization of the target protein; and (3) a reactive unit 
for the covalent attachment of the reporter unit to the target 
protein. For example, Hamachi et al. recently developed several 
labelling protocols based on ligand-directed tosyl chemistry.5 
However, the reactive units of these tosyl chemistry-based 
reagents are only weakly activating, which can sometimes lead 
to the labelling of non-target proteins in a ligand-independent 
manner. The reactivities of certain groups can be carefully 
tuned against non-target proteins to highly stable labelling 
reagents under physiological conditions.6,7 The labelling of non-
target proteins with an activated reagent has been reported to 
be largely insignificant. However, we envisaged that the 
development of an unprecedented labelling reagent that is 
efficiently activated by binding to its target, but remains 
otherwise unreactive would be an ideal tool for protein labelling. 
As part of our ongoing efforts towards the chemical synthesis of 
proteins using N-sulfanylethylanilide (SEAlide) peptide as a 
crypto-thioester,8 we envisioned that application of the SEAlide 
unit to the labelling of proteins could result in the development 
of unprecedented labelling reagents as mentioned above. The 
amide-type SEAlide remains intact in the absence of phosphate 
salts and does not undergo acylation reactions with any of the 
nucleophilic functional groups found on peptides/proteins. 
However, the addition of a phosphate salt induces the N–S-acyl-
transfer-mediated conversion of the stable amide species to the 
corresponding reactive thioester, which can acylate a variety of 
different nucleophiles (Scheme 1A).9, 10 In this case, the 
phosphate salt acts as an acid-base catalyst, facilitating the N–S 
acyl transfer under neutral conditions. Protein surfaces are 
composed of numerous hydrophilic groups including carboxyl, 
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imidazole, amino and guanidine groups, which can function 
cooperatively as acid-base catalysts for the N–S acyl transfer. 
With this in mind, we hypothesized that the unactivated amide-
type SEAlide moiety could be immobilized on the surface of a 
protein, where it could be converted to an active thioester-type 
SEAlide through a side chain-driven N–S acyl transfer. The 
resulting thioester could then show considerable promise as a 
reactive unit for the development of affinity-based labelling 
reagents (Scheme 1B). Based on our hypothesis, we designed a 
SEAlide-based labelling reagent (SEAL) bearing a SEAlide unit to 
allow for the formation of a connection the ligand and reporter 
units as shown in Scheme 1. By not interacting with the target, 
the SEAL would remain in its amide form. This would therefore 
prevent the SEAL from acting as an acylating agent because it 
would not be efficiently concentrated on the protein surface, 
which would be required as an acid-base catalyst. In contrast, 
the binding of the SEAL to the target protein via the formation 
of specific interactions between the ligands and targets would 
allow for the labelling reagent to be concentrated for a certain 
period on the target protein, allowing it to work as an acid-base 
catalyst. This would therefore result in the N–S-acyl-transfer 
acylation of the nucleophilic residues in a ligand-dependent 
manner. 
 
 
 
Scheme 1 Design of the SEAL. A) Phosphate catalyzed activation of the 
SEAlide unit via N–S acyl transfer. A plausible mechanism for this 
transformation is shown in parentheses; B) Concept for the affinity 
labelling of a target protein using SEAL. 
 
Based on this hypothesis, we prepared unreactive amide-type 
SEALs and successfully applied this labelling reagent to the 
selective affinity-based labelling of two model proteins, 
including human carbonic anhydrase (hCA) and cyclooxygenase 
1 (COX-1). 
 
 
Results and discussion 
Molecular design of the SEAL 
The cytosolic protein hCA was selected as a model target 
protein for a proof of concept study. Benzenesulfonamide (SA) 
was used as a specific ligand for hCA.11-13  
 
 
 
 
 
Fig. 1 Selective protein labelling using SEAL. A) Chemical structures of 
the SEALs containing the SA ligand for hCA and two different reporters 
(i.e., biotin and FTC). B and C) Chemical structures of SEALs 1–4. D) SDS-
PAGE analysis for the covalent labelling of purified hCA1 with 1, 2 and 3 
in a test tube. Reaction conditions: hCA1 (10 M) and the SEAL (100 M) 
were incubated in 50 mM HEPES buffer (pH 7.2) at 37 °C for 72 h. E) 
Time course experiment for the labelling of hCA1 with 1. Reaction 
conditions: hCA1 (10 M) and SEAL 1 (100 M) were incubated in 50 
mM HEPES buffer (pH 7.2) at 37 °C for the specified time. 
 
A fluorescein-thiocarbamoyl (FTC) group or biotin was used as a 
reporter unit. The SA ligand and reporter units were connected 
by SEAlide to give the SEALs shown in Fig. 1A. Flexible ethylene 
glycol (mini-PEG) linkers of various lengths were also embedded 
into the SEALs. The incorporation of an S-protected SEAlide unit 
as a stable synthetic intermediate allowed for the desired SEALs 
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to be readily prepared using standard 9-
fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase 
protocols, representing a considerable advantage over other 
techniques generally used for the synthesis of labelling reagents.  
 
 
Optimization of the structure of the SEAL 
We initially evaluated  a variety of mini-PEG linkers of different 
lengths to determine which one would allow for most efficient 
labelling of hCA. FTC-modified SEALs 1-3 were prepared bearing 
varying numbers of mini-PEG repeats and incubated with 
purified hCA1 (10 M) at 37 °C in 50 mM HEPES buffer (pH 7.2). 
Aliquots of the different reaction mixtures containing FTC-
labelled hCA1 were collected every 24 h and analyzed by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
fluorescence gel imaging (FL). The results revealed that the 
incubation experiment involving 1 (n=0 for the chain length) 
afforded maximal fluorescence intensity (Fig. 1D, Lane 1). This 
effect was found to be specific for 1 highlighting the selective 
nature of this SEAL for hCA1 based on the specificity of the 
ligand for the ligand-binding cavities of the target protein, 
which is crucial for efficient labelling. Notably, the labelling of 
hCA1 with 1 reached a plateau within 48 h. (Fig. 1E).  
We also examined whether SEALs worked through site-specific 
labelling. In this case, the use of the dual modified SEAL 4 
containing biotin and a FTC group allowed for the labelled and 
unlabelled hCA1 proteins to be individually detected by SDS-
PAGE. Purified hCA1 (10 M) was incubated with 4 (100 M) at 
37 °C in 50 mM HEPES buffer (pH 7.2). The labelled hCA1 was 
isolated by SDS-PAGE and subjected to proteolytic digestion 
using trypsin in the gel, and the resulting digested peptide 
fragments were extracted from the gel and analysed by nanoLC-
MS/MS. The resulting of this analysis revealed that Lys137, 
which is located in close proximity to the ligand-binding site, 
was labelled with the reporter (Fig. S1). 
 
 
Selective labelling of target proteins 
The labelling selectivity of SEAL 1 was subsequently examined 
using a protein mixture containing hCA1, enolase, ovalbumin 
(OVA) and glutathione S-transferase (GST). The protein mixture 
was incubated with 1 for 48 h at 37 °C in 50 mM HEPES buffer 
(pH 7.2). The resulting mixture was analyzed by SDS-PAGE, 
followed by fluorescence gel imaging, which revealed the 
present of a strong fluorescence band corresponding to the 
FTC-labelled hCA1 (Fig. 2). These results therefore 
demonstrated that we could achieve the selective labelling of a 
target protein using the SEAL system in a mixture of different 
proteins, whilst leaving the none-target protein unchanged.  
To verify the versatility of these SEAL system for the selective 
labelling of target proteins, we attempted to label 
cyclooxygenase 1 (COX-1) using a SEAL containing indomethacin 
(IM), which is well-known as a specific ligand for COX enzyms.14 
SEAL 5 was therefore synthesized containing  biotin as a 
reporter (Fig. 3A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 SDS-PAGE analysis of the selective labelling of hCA1 with 1 in a 
protein mixture consisting of four different proteins in a test tube. 
Reaction conditions: enolase, GST, hCA1 and OVA (10 M each) were 
incubated with 1 (100 M) in 50 mM HEPES buffer (pH 7.2) at 37 °C for 
48 h. 
 
 
A mixture of Tris·HCl buffer (pH 8.0) containing bovine serum 
albumin (BSA), COX-1 and enolase was incubated with 5 for 48 
h at 4 °C. Notably, this experiment was conducted at 4 °C 
because COX-1 was found to be unstable at 37 °C in aqueous 
buffer in the absence of a stabilizer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 SDS-PAGE analysis for the selective labelling of COX-1 in a protein 
mixture. A) Chemical structure of 5, bearing indomethacin (IM) as a 
ligand for COX-1 labelling. B) SDS-PAGE analysis for the labelling of COX-
1 with 5 in a mixture of three different proteins. Reaction conditions: 
BSA, COX-1 and enolase (1.4 M each) were incubated with 5 (14 M) 
in 80 mM Tris·HCl buffer (pH 8.0) at 4 °C for 48 h. 
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The incubation mixture was subsequently analyzed by SDS-
PAGE, which revealed the presence of a single biotin-labelled 
protein using a streptavidin-horseradish peroxidase conjugate 
(SAv-HRP). Fig. 3B shows that a single band corresponding 
biotinylated-COX-1 was detected at approximately 64 kDa. 
 
 
Labelling of intracellular hCA 
We also investigated the application of this strategy to 
intracellular protein labelling by attempted the selective 
labelling of endogenous hCA using a SEAL in human red blood 
cells (RBCs).15 Low molecular weight hydrophobic compounds 
can generally permeate through cell membranes much more 
effectively than high molecule hydrophilic compounds.16 With 
this in mind, we designed and synthesized SEAL 6 to provide 
improved membrane permeability and enhanced labelling 
efficiency towards intracellular proteins compared with SEAL 1. 
Notably, SEAL 6 had a low molecular weight than 1 and lacked 
the hydrophilic mini-PEG linker (Fig. 4A). RBCs were incubated 
in HEPES-buffered saline (HBS) containing 6 (200 M) for 48 h 
at 37 °C, before being  washed three times with fresh HBS. 
 
 
 
 
 
 
Fig. 4 Intracellular hCA labelling with 6 in RBCs. A) Chemical structure of 
6. B) SDS-PAGE analysis for the labelling of the endogenous hCA in RBCs. 
The bands were detected with streptavidin-HRP. The bands with a single 
asterisk (*) correspond to hCA, whereas those with the double asterisk 
(**) corresponds to non-specific detected with streptavidin-HRP band. 
Reaction conditions: RBCs were incubated with 6 (100 M) in HEPES-
buffered saline (HBS, pH 7.2) at 37 °C for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Elucidation of the mechanism for the SEAL-mediated labelling of 
the proteins. A) Chemical structure of 7. B) SDS-PAGE analysis to 
determine the mechanism of this SEAL-mediated labelling process. 
Reaction conditions: Purified COX-1 (1.4 M) was incubated with 5 or 7 
(14 M) in 80 mM Tris·HCl buffer (pH 8.0) at 4 °C for 48 h. 
 
 
The RBCs were then lysed and the resulting lysate was analyzed 
by SDS-PAGE, followed by detection with SAv-HRP, which 
revealed a single band corresponding to biotinylated-hCA at 
approximately 37 kDa (Fig. 4B). Notably, we did not observe the 
SA-dependent labelling of the target protein in the presence of 
ethoxyzolamide (EZA), which is a strong binder against the SA-
binding pocket of hCA.17 These results therefore demonstrated 
that the use of hydrophobic and low molecular weight SEAL 
bearing a SA ligand could be used as an efficiently strategy for 
the intracellular labelling of hCA in a ligand-dependent fashion.  
 
 
Elucidation of the mechanism of this SEAL-mediated labelling 
process 
The potential involvement of the N–S acyl transfer of the 
SEAlide moiety during this protein labelling process was 
examined the using S-protected SEAL derivative 7 (Fig. 5A). COX-
1 was incubated with 7 in 80 mM HEPES buffer (pH 8.0) for 48 h 
at 4 °C. However, the subsequent analysis of this mixture by 
SDS-PAGE revealed that none of the COX-1 has been labelled, 
and thereby indicated that the N–S acyl transfer reaction was a 
critical step in the protein labelling process (Fig. 5B).  
Finally, we attempted to address the issue of whether the 
surface of the protein acts as an acid-base cluster catalyst to 
enhance the N–S acyl transfer reaction. Although we have not 
yet collected any direct evidence to suggest that the N–S acyl 
transfer reaction is accelerated by acid-base residues on protein 
surfaces, we have collected the following anecdotal evidence: 
(1) SEAL 6 remained intact in the presence of a large amount of 
amine or cysteine methyl ester in HEPES buffer (Fig. S2). (2) 
SEALs immobilized on protein surfaces in a ligand-dependent 
manner could modify Lys--amino group which would present 
themselves in a stoichiometric ratio relative to the SEAL under 
the labelling conditions. 
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Conclusions 
We have developed a new type of protein-labelling reagent 
“SEAL” that features a SEAlide moiety with tunable electrophilic 
reactivity. These SEAL systems were readily obtained using 
standard Fmoc-based solid-phase protocols. Electrophilically 
unreactive amide-type SEAlides can be converted to the 
corresponding electrophilically reactive thioester-type SEAlides 
in the presence of a phosphate salt, which can act as an acid-
base catalyst. With this in mind, we hypothesized that the acidic 
and basic residues found on protein surfaces could function as 
acid-base catalysts for the N–S acyl transfer reaction of a SEAL 
system. It was therefore envisioned that the binding of a SEAL 
to the surface of a target protein in a ligand-dependent manner 
could be followed by the activation of the SEAL to a reactive 
thioester to electrophilic labelling of the target protein. hCA and 
COX-1 were used as model target proteins with SEAL 1 (hCA-1 
ligand) and 5 (COX-1 ligand), respectively, which selectively 
labelled the target proteins in a mixture of proteins. We also 
developed a hydrophobic low molecular weight SEAL without a 
mini-PEG linker that we used to label intracellular hCA1 in RBCs. 
Taken together, these results highlight the potential of SEALs as 
protein-labelling reagent. However, one issue remains 
unresolved, and that is whether the significant difference 
observed between our newly developed SEALs and 
conventional labelling reagents can be attributed to the 
activation of the labelling reagents by the protein surface. 
Although we collected indirect evidence for the activation of the 
SEAL by the protein surface, based on the fact that it remained 
unreactive in the presence of a large excess of amine, the 
acquisition of direct evidence remains challenging. Research 
towards obtained direct evidence for the surface-mediated 
activation of these SEAL system, as well as extending their utility 
to other ligand-protein pairs including target naïve ligands, is 
currently underway in our lab. These results will be reported in 
due course. 
 
Experimental 
General procedures 
All reactions of small molecules were carried out under a 
positive presser of argon. For column chromatography, silica 
Gel 60 N (sperical, neutral, Kanto Chemical Co. Inc.) was 
employed. Thin layer chromatography was performed on 
precoated plates (0.25 nm, silica gel Merck Kiesegel 60F245). 
Mass spectra were recorded on a Waters MICROMASS® LCT 
PRIMETM (ESI-TOF) or a Bruker Esquire2000T (ESI-Ion trap). NMR 
spectra were recoded using a Bruker AV400N at 400 MHz 
frequency for 1H and a JEOL JNM-AL300 at 75 MHz frequency 
for 13C in methanol-d4. Chemical shifts are calibrated to the 
solvent signal. For HPLC separations, a Cosmosil 5C18-AR-II 
analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1 
mL/min) or a 5C18-AR-II preparative column (Nacalai Tesque, 20 
× 250 mm, flow rate 10 mL/min) was employed, and eluting 
products were detected by UV at 220 nm. A solvent system 
consisting of 0.1% (v/v) TFA aqueous solution (solvent A) and 
0.1% (v/v) TFA in MeCN (solvent B) was used for HPLC elution. 
Fluorescence and chemiluminescent signals were detected with 
LAS-4000mini (Fujifilm). 
 
Synthetic of SEALs 
SEALs were prepared by Fmoc-solid phase protocols using 
Fmoc-mini-PEGTM, Fmoc-Gly-SEAlide-OH8d, Fmoc-L-Lys(4-
sulfamoyl-benzoyl)-OH (for hCA1 labelling) and Fmoc-L-
Lys(ivDde)-OH (for COX-1 labelling). 
 
Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH 
To a stirred solution of Fmoc-L-Lys-OH (346 mg, 0.940 mmol) in 
DMF (2.5 mL) were added 4-sulfamoylbenzoic acid N-
hydroxysuccinimide ester (365 mg, 1.22 mmol) and DIPEA (486 
L, 2.82 mmol), and the reaction mixture was stirred for 3.5 h. 
The mixture was concentrated in vacuo, and the obtained 
residue was dissolved in EtOAc. The organic layer was washed 
with 5% (w/v) aqueous citric acid, H2O and brine, dried over 
MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (CHCl3/MeOH = 9:1) and 
427 mg of Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH (0.754 mmol, 
80%) was obtained as a white powder: []19D 2.79 (c 0.64, 
CH3OH); 1H NMR (400 MHz, CD3OD) = 1.45-1.58 (m, 2H), 1.58-
1.81 (m. 3H), 1.91 (m, 1H), 3.42 (t, J = 7.0 Hz, 2H), 4.18 (dd, J = 
4.4, 9.2 Hz, 1H), 4.24 (t, J = 6.8 Hz, 1H), 4.34 (dd, J = 6.8, 10.7 Hz, 
1H), 4.39 (dd, J = 6.8, 10.7 Hz, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.40 
(t, J = 7.0 Hz, 2H), 7.68 (d, J = 7.6 Hz, 2H), 7.70 (d, J = 7.6 Hz, 1H), 
7.81 (d, J = 7.6 Hz, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 
Hz, 2H), 13C NMR (75 MHz, CD3OD): =24.4, 29.9, 32.3, 40.9, 
55.2, 67.9, 120.9, 126.2, 127.3, 128.1, 128.8, 129.0, 142.6, 145.2, 
145.3, 147.6, 158.7, 168.8, 175.9; HRMS (ESI-TOF) m/z calcd for 
C28H29N3O7NaS ([M+Na]+) 574.1624, found 574.1625) 
 
Synthesis of SEAL 1 
Synthesis of SEAL 1 was performed by using Fmoc-based solid-
phase protocols on NovaSyn® TGR resin (loading: 0.22 mmol/g, 
45 mg, 0.010 mmol). Coupling of Fmoc-L-Lys(4-sulfamoyl-
benzoyl)-OH (17 mg, 0.030 mmol) with the aid of DIC (4.6 L, 
0.030 mmol)/HOBt·H2O (4.6 mg, 0.030 mmol) in DMF was 
performed, and treatment with 20% (v/v) piperidine in DMF was 
used for the removal of Fmoc protection to give a resin. Fmoc-
Gly-SEAlide-OH (1.4 mg, 0.020 mmol) was coupled on the 
resulting resin by HATU (7.2 mg, 0.019 mmol) and DIPEA (3.3 L, 
0.019 mmol) in DMF at room temperature in DMF for 2 h. After 
deprotection of Fmoc group with 20% (v/v) piperidine in DMF, 
coupling of Fmoc-mini-PEGTM (12 mg, 0.030 mmol) in DMF were 
conducted by Fmoc-based solid-phase protocols. To obtained 
resin were added fluorescein-5-isothiocyanate (FITC, 9.7 mg, 
0.025 mmol) and DIPEA (43 L, 0.025 mmol) in DMF, and the 
reaction was performed for 2 h. The resulting completed resin 
was treated with TFA-TES-H2O (95:2.5:2.5, 3.3 mL) for 2h. After 
filtration of the resin, the filtrate was concentrated to provide 
the crude product. The obtained crude product was purified by 
preparative HPLC to yield SEAL 1 (1.51 mg, 14%, an yellow 
lyophilized powder). Analytical HPLC conditions: gradient of 
solvent B in solvent A, 10-60% over 30 min. Retention time = 
20.9 min. Preparative HPLC conditions: linear gradient of 
solvent B in solvent A, 30 to 40% over 30 min. MS (ESI-TOF) m/z 
calcd for C51H54N8O14S3  ([M+H]+): 1099.3, found 1099.6. 
 
Synthesis of SEAL 2 
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SEAL 2 was synthesized in a manner similar to that employed in 
the synthesis of SEAL 1. NovaSyn® TGR resin (loading: 0.22 
mmol/g, 45.0 mg, 0.01 mmol) was used to yield SEAL 2 (2.85 mg, 
23%, an yellow lyophilized powder). Analytical HPLC conditions: 
gradient of solvent B in solvent A, 10-60% over 30 min. 
Retention time = 20.7 min. Preparative HPLC conditions: linear 
gradient of solvent B in solvent A, 30 to 40% over 30 min. MS 
(ESI-TOF) m/z calcd for C57H65N9O17S3  ([M+H]+): 1244.4, found 
1244.8. 
 
Synthesis of SEAL 3 
SEAL 3 was synthesized in a manner similar to that employed in 
the synthesis of SEAL 1. NovaSyn® TGR resin (loading: 0.22 
mmol/g, 45.0 mg, 0.01 mmol) was used to yield SEAL 3 (2.90 mg, 
21%, an yellow lyophilized powder). Analytical HPLC conditions: 
gradient of solvent B in solvent A, 10-60% over 30 min. 
Retention time = 20.4 min. Preparative HPLC conditions: linear 
gradient of solvent B in solvent A, 29 to 39% over 30 min. MS 
(ESI-TOF) m/z calcd for C63H76N10O20S3 ([M+H]+): 1389.5, found 
1389.9. 
 
Synthesis of SEAL 4 
SEAL 4 was synthesized in a manner similar to that employed in 
the synthesis of SEAL 1 on NovaSyn® TGR resin (loading: 0.22 
mmol/g, 227 mg, 0.050 mmol). Coupling of Fmoc-L-Lys(4-
sulfamoyl-benzoyl)-OH (85 mg,  0.15 mmol) with the aid of DIC 
(23 L, 0.15 mmol)/HOBt·H2O (20 mg, 0.15 mmol) in DMF was 
performed, and treatment with 20% (v/v) piperidine in DMF was 
used for the removal of Fmoc protection to give a resin. Fmoc-
Gly-SEAlide-OH (72 mg, 0.10 mmol) was coupled on the 
resulting resin by using HATU (36 mg, 0.095 mmol) and DIPEA 
(17 L, 0.095 mmol) in DMF at room temperature for 2 h. After 
deprotection of Fmoc group of the resulting resin with 20% (v/v) 
piperidine in DMF, stepwise coupling of Fmoc-mini-PEGTM (58 
mg, 0.15 mmol) in DMF, Fmoc-Lys(ivDde)-OH (86 mg, 0.15 
mmol) in DMF and biotin (61 mg, 0.25 mmol) in DMF-DMSO (3:1 
(v/v)) were conducted by Fmoc-based solid-phase protocols. 
The ivDde group on the Lys residue was removed by treatment 
with 2% (v/v) hydrazine monohydrate in DMF for 17 h, and the 
generated amine was treated with FITC (49 mg, 0.13 mmol) in 
DMF and DIPEA (22 L, 0.13 mmol) for 5 h. The resulting 
completed resin was treated with TFA-TES-H2O (95:2.5:2.5, 16 
mL) for 2h. After filtration of the resin, the filtrate was 
concentrated to provide a crude product. The obtained crude 
product was purified by preparative HPLC to yield SEAL 4 (22.0 
mg, 28%, an yellow lyophilized powder).Analytical HPLC 
conditions: gradient of solvent B in solvent A, 10-60% over 30 
min. Retention time = 19.5 min. Preparative HPLC conditions: 
linear gradient of solvent B in solvent A, 28 to 38% over 30 min. 
MS (ESI-TOF) m/z calcd for C79H102N14O23S3 ([M+2H]2+): 799.6, 
found 799.5. 
 
Synthesis of SEAL 5 
SEAL 5 was synthesized in a manner similar to that employed in 
the synthesis of SEAL 4. NovaSyn® TGR resin (loading: 0.25 
mmol/g, 160 mg, 0.040 mmol) was used to yield SEAL 5 (0.38 
mg, 0.6%, a white lyophilized powder). Analytical HPLC 
conditions: gradient of solvent B in solvent A, 10-60% over 30 
min. Retention time = 25.7 min. Preparative HPLC conditions: 
linear gradient of solvent B in solvent A, 38 to 48% over 30 min. 
MS (ESI-TOF) m/z calcd for C70H99ClN12O20S2 ([M+H]+): 1527.6, 
found: 1527.9. 
 
Synthesis of SEAL 6 
SEAL 6 was synthesized in a manner similar to that employed in 
the synthesis of SEAL 1. NovaSyn® TGR resin (loading: 0.24 
mmol/g, 208 mg, 0.050 mmol) was used to yield SEAL 6 (13 mg, 
33%, a white lyophilized powder). Analytical HPLC conditions: 
gradient of solvent B in solvent A, 10-60% over 30 min. 
Retention time = 16.8 min. Preparative HPLC conditions: linear 
gradient of solvent B in solvent A, 23 to 33% over 30 min. MS 
(ESI-TOF) m/z calcd for C34H46N8O8S3 ([M+H]+):791.3, found: 
791.1. 
 
Synthesis of SEAL 7 
To a solution of SEAL 5 (10.6 mg, 6.87 mol) in DMF was added 
MeI (69.0 L, 1.11 mmol) and DIPEA (69.0 L, 6.87 mol) with 
stirring at room temperature for 1 h. The reaction mixture was 
purified by preparative HPLC to yield SEAL 7 (4.43 mg, 42%, a 
white lyophilized powder). Analytical HPLC conditions: gradient 
of solvent B in solvent A, 10-60% over 30 min. Retention time = 
25.9 min. Preparative HPLC conditions: linear gradient of 
solvent B in solvent A, 35 to 49% over 30 min. MS (ESI) m/z calcd 
for C71H101ClN12O20S2  ([M+H]
+): 1541.7, found 1541.7. 
 
Optimization of structure of SEALs 
Purified human carbonic anhydrase 1 (hCA1) was purchased 
from SIGMA-Aldrich and used without further purification. The 
hCA1 (10 M) with 1-3 (100 M) was incubated at 37 °C in 50 
mM HEPES buffer (pH 7.2). At every 24 h, the reaction aliquots 
were subjected to ultrafiltration (14,000 g, 15 min, himac CT 
15RE (Hitachi Koki Co., Ltd.)) using Amicon® Ultra-0.5 
Centrifugal Filter Devices (Merck Millipore) and the concentrate 
was mixed with the same volume of 2×SDS sample loading 
buffer followed by heating at 100 °C for 5 min. The heated 
reaction mixtures were analyzed using SDS-PAGE in 14% in 
polyacrylamide gels. For the chemiluminescence imaging of the 
biotinylated proteins, the proteins were transferred to 
Amersham Hybond-P PVDF Membrane (GE Healthcare) and 
detected with a streptavidin-horseradish peroxidase conjugate 
(SAv-HRP, GE Healthcare) and ECL plus Western Blotting 
Detection System (GE Healthcare).  For silver staining of all 
proteins, proteins in a gel were stained with Silver Stain KANTO
Ⅲ (KANTO CHEMICAL CO., INC.). 
To determaine that the labelling of hCA1 was site-specifically 
occurred, purified hCA1 (10 M) was labelled using 4 (100 M) 
according to the method described above. The labelled hCA1 
was subjected to SDS-PAGE in 14% in polyacrylamide gel and 
stained with CBB Stain One (Nacalai tesqe). The gel containing 
of the labelled hCA1 with trypsin was incubated at 37 °C in 
Tris·HCl buffer (pH 8.0) for 20 h. The digested labelled-hCA1 was 
analyzed on nanoLC-MS/MS. 
LC: UltiMate 3000 RSLCnano system (Thermo Fisher Scientific 
Inc.) 
MS: Orbital Elite (Thermo Fisher Scientific Inc.) 
Column: Acclaim PepMap RSLC Nano Column (75 m×15 cm, 
Thermo Fisher Scientific Inc.) 
Solvent A: 0.1% formic acid aq.; solvent B 0.08% formic 
acid/80% MeCN aq. 
 
Selective labelling of hCA1 in protein mixture 
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A protein mixture containing of enolase, GST, hCA1 and OVA (10 
M each, purchased from SIGMA) with 1 (100 M) was 
incubated in 50 mM HEPES buffer (pH 7.2) at 37 °C for 48 h. The 
reaction mixture was subjected to ultrafiltration and the 
concentrated mixture was blended with the same volume of 2
×SDS sample loading buffer followed by heating at 100 °C for 5 
min. The heated samples were applied to 14% SDS-PAGE, and 
analyzed by in-gel fluorescence imaging and silver-staining. 
 
Selective labelling of COX-1 in protein mixture 
As a protein mixture, BSA purchased from SIGMA, 
cyclooxygenase 1 (COX-1) purchased from Cayman Chemical 
and enolase (1.4 M each) was used. 
The mixture of proteins with 6 was incubated in 80 mM Tris·HCl 
buffer (pH 8.0) at 4 °C for 48 h. The reaction mixture was 
analyzed using SDS-PAGE in 10% polyacrylamide gels followed 
by chemiluminescence imaging according to the methods 
described above. For silver staining of all proteins, proteins in a 
gel were stained with Silver Stain KANTOⅢ. 
 
Intracellular protein labelling 
Human red blood cells (hRBCs) were purchased from BizCom 
Japan, Inc., and purified by the use of a centrifugation (3,000 g, 
15 min). Purified hRBCs were resuspended in HEPES-buffered 
saline (HBS) and incubated with 5 (200 M) in the absence or 
presence of ethoxyzolamide (EZA, 2 mM) at 37 °C for 48 h. The 
incubated hRBCs were washed three times with HBS and lysed 
by sonication. The resulting lysate was centrifuged (12,000 g, 30 
min) and the resulting supernatant was collected and separated 
with 5 by the use of ultrafiltration. The resulting mixture was 
analyzed using SDS-PAGE in 10% polyacrylamide gels followed 
by chemiluminescence imaging according to the methods 
described above. For silver staining of all proteins, proteins in a 
gel were stained with Silver Stain KANTOⅢ. 
 
Elucidation of a mechanism of the labelling using a SEAL 
Purified COX-1 (1.4 M) was incubated with 6 or 7 (14 M) in 
80 mM Tris·HCl buffer at 4 °C for 48 h. The reaction mixtures 
were subjected to ultrafiltration followed by SDS-PAGE analysis. 
The biotinylated COX-1 was detected with SAv-HRP using ECL 
plus Western Blotting Detection System.  
The immunodetection of COX-1 was accomplished with COX-1 
monoclonal antibody and anti-mouse IgG-HRP conjugate (both 
Santa Cruz Biotechnology). 
To demonstrate of the stability of 5, butylamine (1 M) and 5 (10 
M) were incubated in 50 mM HEPES buffer (pH 7.2) at 37 °C. 
At every 24 h, reaction aliquots containing 5 were analyzed by 
HPLC. 
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